AB Science SA AI Stock Analysis
Want to see FR:AB full AI Analyst Report?
AB Science SA (AB) AI Stock Analysis
AB Science SA
(Paris:AB)
The score is driven primarily by weak financial performance (persistent losses, negative equity, and renewed free-cash-flow burn), which elevates financing and solvency risk. Technicals add pressure with a clear downtrend across key moving averages, only partially offset by oversold readings. Valuation provides limited support because the company is loss-making (negative P/E) and offers no stated dividend yield.
AB Science SA (AB) vs. iShares MSCI France ETF (EWQ)
- Market Cap
- EUR 82.04M
- Dividend Yield
- ―
- Average Volume (3M)
- 241.30K
- Price to Earnings (P/E)
- -6.6
- Beta (1Y)
- 1.39
- Revenue Growth
- 12.66%
- EPS Growth
- 44.01%
- Country
- France
- Employees
- 33
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Drug Manufacturers - Specialty & Generic
AB Science SA Business Overview & Revenue Model
Company Description
AB Science S.A. is a pharmaceutical company dedicated to the discovery, development, and commercialization of protein kinase inhibitors for applications in both human and animal health. Its primary drug candidate, masitinib, a tyrosine kinase inhibit...
How the Company Makes Money
AB Science’s business model is centered on developing proprietary drug candidates and monetizing them through (i) commercial sales if/when products obtain marketing authorization and are launched, and/or (ii) partnering transactions (e.g., out-licens...
AB Science SA Financial Statement Overview
Summary
Overall financial strength is very weak: the company remains deeply unprofitable with persistent net losses, shareholder equity is negative (a major solvency risk), and free cash flow returned to significant burn in 2025. Debt reduction by 2025 is a positive, but it does not offset the continued losses and fragile capital structure.
Income Statement
26NegativeBalance Sheet
22NegativeCash Flow
24Negative| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 1.16M | 1.17M | 1.07M | 970.00K | 958.00K | 1.61M |
| Gross Profit | 361.00K | 720.00K | 1.25M | 587.00K | 927.00K | 1.50M |
| EBITDA | -9.01M | -1.22M | -4.92M | -11.16M | -13.41M | -17.36M |
| Net Income | -5.41M | -1.56M | -7.83M | -10.05M | -13.62M | -14.46M |
Balance Sheet | ||||||
| Total Assets | 18.09M | 24.52M | 23.18M | 25.50M | 23.84M | 21.27M |
| Cash, Cash Equivalents and Short-Term Investments | 8.98M | 10.18M | 7.99M | 6.07M | 7.27M | 8.72M |
| Total Debt | 4.74M | 4.24M | 18.47M | 19.10M | 23.96M | 8.35M |
| Total Liabilities | 35.15M | 34.34M | 46.93M | 46.51M | 59.51M | 44.47M |
| Stockholders Equity | -22.45M | -17.20M | -23.75M | -21.01M | -35.67M | -23.20M |
Cash Flow | ||||||
| Free Cash Flow | -4.74M | -4.57M | 370.00K | -17.22M | -18.11M | -17.74M |
| Operating Cash Flow | -4.54M | -4.29M | 525.00K | -16.87M | -17.47M | -17.18M |
| Investing Cash Flow | -121.00K | -224.00K | -136.00K | -614.00K | -360.00K | -590.00K |
| Financing Cash Flow | 8.61M | 6.69M | 1.53M | 16.27M | 16.39M | 5.84M |
AB Science SA Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For FR:AB, the sentiment is Negative. The current price of 0.53 is below the 20-day moving average (MA) of 0.54, below the 50-day MA of 0.61, and below the 200-day MA of 0.90, indicating a bearish trend. The MACD of -0.02 indicates Negative momentum. The RSI at 43.72 is Neutral, neither overbought nor oversold. The STOCH value of 36.98 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for FR:AB.
AB Science SA Peers Comparison
Overall Rating
FR:SAN79Outperform
FR:IPN71Outperform
FR:IPH43Neutral- FR:AB41Neutral
FR:ALCLS39Underperform
FR:OSE37Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| FR:SAN | 79Outperform | EUR 103.10B | 24.63 | 5.84% | 4.79% | 15.30% | -35.58% |
| FR:IPN | 71Outperform | EUR 13.73B | 26.77 | 11.33% | 0.96% | 13.63% | 14.45% |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| FR:IPH | 43Neutral | EUR 147.44M | -2.59 | 152.56% | ― | -29.48% | 7.91% |
| FR:AB | 41Neutral | EUR 51.55M | -6.63 | 27.28% | ― | 12.66% | 44.01% |
| FR:ALCLS | 39Underperform | EUR 75.87M | -1.79 | -94.14% | ― | -5.98% | -8.67% |
| FR:OSE | 37Underperform | EUR 40.04M | -1.01 | -96.73% | ― | -96.25% | -197.89% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| FR:AB | Ab Science | 0.53 | -0.65 | -54.75% | |
| FR:IPH | Innate Pharma S.A. | 1.32 | -0.29 | -17.81% | |
| FR:IPN | Ipsen | 166.00 | 36.67 | 28.36% | |
| FR:OSE | OSE Immunotherapeutics | 1.70 | -3.94 | -69.82% | |
| FR:SAN | Sanofi | 85.95 | 0.30 | 0.35% | |
| FR:ALCLS | Cellectis SA | 1.05 | -2.16 | -67.32% |
AB Science SA Corporate Events
AB Science Schedules Investor Web Conference to Detail Governance and Growth Outlook
AB Science SA plans to hold a web conference on October 14, 2026, aimed at updating stakeholders on strategic and operational developments following recent governance changes. The session will be conducted in French with English materials and will in...
AB Science Overhauls Strategy as Loss Widens but Financing and Trials Advance
AB Science has launched a major governance overhaul with the appointment of Stéphane Ledermann as chairman and chief executive, marking a strategic relaunch aimed at extracting more value from its pipeline and assets. The new plan prioritises a reinf...
AB Science Resets Clinical Timelines After GCP Inspection and Strengthens Quality Strategy
AB Science has revised its development plan and financial calendar after a multi-country Good Clinical Practice inspection of its sponsored trials, reinforcing new management’s decision to prioritize a strengthened quality management system and proto...
AB Science Completes €14.2 Million Private Placement, Bolstering Funding for Drug Pipeline
AB Science has completed the settlement and delivery of securities issued under a €14.2 million private placement subscribed by a limited number of investors, involving new ordinary shares with attached share subscription warrants that could raise th...
AB Science Raises €14.2 Million to Drive R&D and Strategic Transformation
AB Science has completed a €14.2 million private placement, largely subscribed by an existing long-term investor, bringing its cash position to around €23 million and covering working capital needs beyond the next 12 months. The CEO also participated...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Sep 30, 2026